Description
Parallel trade of pharmaceuticals in the European Union has grown consistently despite numerous challenges from some of the industry s biggest players. The principles of free movement of goods and the regional exhaustion of intellectual property rights have helped parallel traders to make millions and the European Court of Justice has consistently ruled in their favour on cases relating to trademark issues. In response, pharmaceutical companies are now looking towards other ways of addressing parallel trade.
SMi s 5th annual Pharmaceutical Parallel Trade 2011 conference will feature a variety of informational presentations from expert speakers with differing opinions and perspectives to offer. There will be an emphasis on the importance of effective supply chain management and pricing strategy as well as insights in to the impact of direct-to-pharmacy distribution and recent competition law developments.
